Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
myotonic dystrophy Type 1
Biotech
Novartis’ centerpiece of $12B Avidity deal flunks ‘crucial’ test
The flop leaves Novartis with one win and two failures from a rapid-fire run of key clinical readouts.
Nick Paul Taylor
Sep 8, 2026 3:34am
Sarepta's big bet on Arrowhead's siRNA assets yields early data
Mar 25, 2026 9:35am
PepGen hit with partial hold, analyst blames 'understaffed FDA'
Mar 5, 2026 5:45am
Sarepta shares safety update on DM1 RNA med
Nov 24, 2025 4:00pm
PepGen ends all DMD work after phase 2 trial falls flat
May 28, 2025 5:30pm
RNA-targeting drug relaxes muscles in myotonic dystrophy mice
Dec 4, 2024 7:00am
